Publications

  1. Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). J Clin Oncol. 2023 Jan 20; 41 (3):472-478 Epub 2022 Sept 06
    View PubMed
  2. Van Blarigan EL, Ma C, Ou FS, Bainter TM, Venook AP, Ng K, Niedzwiecki D, Giovannucci E, Lenz HJ, Polite BN, Hochster HS, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Ciombor KK, Meyerhardt JA. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2023 Jan 15; 152 (2):123-136 Epub 2022 Aug 20
    View PubMed
  3. Symonds L, Yu M, Zhang Y, Ou FS, Zemla TJ, Carter K, Bertagnolli M, Innocenti F, Bosch LJ, Meijer GA, Carvalho B, Grady WM, Cohen SA. Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). Epigenetics. 2022 Dec; 17 (12):1715-1725 Epub 2022 Apr 12
    View PubMed
  4. Johnson RM, Qu X, Lin CF, Huw LY, Venkatanarayan A, Sokol E, Ou FS, Ihuegbu N, Zill OA, Kabbarah O, Wang L, Bourgon R, de Sousa E Melo F, Bolen C, Daemen A, Venook AP, Innocenti F, Lenz HJ, Bais C. ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. Nat Commun. 2022 Sep 19; 13 (1):5478 Epub 2022 Sept 19
    View PubMed
  5. Lee S, Ma C, Zhang S, Ou FS, Bainter TM, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson A, Atienza D, Kindler H, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS. Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance). Oncologist. 2022 Jun 8; 27 (6):e494-e505
    View PubMed
  6. Kulke MH, Ou FS, Niedzwiecki D, Huebner L, Kunz P, Kennecke HF, Wolin EM, Chan JA, O'Reilly EM, Meyerhardt JA, Venook A. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocr Relat Cancer. 2022 May 9; 29 (6):335-344 Epub 2022 May 09
    View PubMed
  7. McCleary NJ, Zhang S, Ma C, Ou FS, Bainter TM, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. J Geriatr Oncol. 2022 May; 13 (4):469-479 Epub 2022 Jan 31
    View PubMed
  8. Innocenti F, Yazdani A, Rashid N, Qu X, Ou FS, Van Buren S, Bertagnolli MM, Kabbarah O, Blanke CD, Venook AP, Lenz HJ, Vincent BG. Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. Clin Cancer Res. 2022 Apr 14; 28 (8):1690-1700
    View PubMed
  9. Lipsyc-Sharf M, Ou FS, Yurgelun MB, Rubinson DA, Schrag D, Dakhil SR, Stella PJ, Weckstein DJ, Wender DB, Faggen M, Zemla TJ, Heying EN, Schuetz SR, Noble S, Meyerhardt JA, Bekaii-Saab T, Fuchs CS, Ng K. Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. Oncologist. 2022 Apr 5; 27 (4):292-298
    View PubMed
  10. Lipsyc-Sharf M, Zhang S, Ou FS, Ma C, McCleary NJ, Niedzwiecki D, Chang IW, Lenz HJ, Blanke CD, Piawah S, Van Loon K, Bainter TM, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg R, O'Reilly EM, Meyerhardt JA, Ng K. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2022 Mar 8; 114 (3):427-435
    View PubMed
  11. Cheng E, Ou FS, Ma C, Spiegelman D, Zhang S, Zhou X, Bainter TM, Saltz LB, Niedzwiecki D, Mayer RJ, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci EL, Van Blarigan EL, Brown JC, Ng K, Gross CP, Meyerhardt JA, Fuchs CS. Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). J Clin Oncol. 2022 Mar 1; 40 (7):740-751 Epub 2022 Jan 07
    View PubMed
  12. Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1; 5 (2):e2149040 Epub 2022 Feb 01
    View PubMed
  13. Van Blarigan EL, Ou FS, Bainter TM, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, Hantel A, Benson AB 3rd, Atienza D, Messino M, Kindler HL, Venook AP, Ogino S, Sanoff HK, Giovannucci EL, Ng K, Meyerhardt JA. Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer. JAMA Netw Open. 2022 Feb 1; 5 (2):e220145 Epub 2022 Feb 01
    View PubMed
  14. Arai H, Elliott A, Millstein J, Xiu J, Ou FS, Innocenti F, Wang J, Battaglin F, Jayachandran P, Kawanishi N, Soni S, Zhang W, Sohal D, Goldberg RM, Hall MJ, Scott AJ, Khushman M, Hwang JJ, Lou E, Weinberg BA, Lockhart AC, Shields AF, Abraham JP, Magee D, Stafford P, Zhang J, Venook AP, Korn WM, Lenz HJ. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. Oncogene. 2022 Jan; 41 (2):260-267 Epub 2021 Nov 02
    View PubMed
  15. Le-Rademacher JG, Therneau TM, Ou FS. The Utility of Multistate Models: A Flexible Framework for Time-to-Event Data. Curr Epidemiol Rep. 2022; 9 (3):183-189 Epub 2022 June 29
    View PubMed
  16. Snyder RA, He J, Le-Rademacher J, Ou FS, Dodge AB, Zemla TJ, Paskett ED, Chang GJ, Innocenti F, Blanke C, Lenz HJ, Polite BN, Venook AP. Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931). Cancer. 2021 Oct 15; 127 (20):3801-3808 Epub 2021 Aug 10
    View PubMed
  17. Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, Mitchell K, Frankel WL, Niedzwiecki D, Noonan A, Janjigian YY, Thurmes PJ, Venook AP, Meyerhardt JA, O'Reilly EM, Ilson DH. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol. 2021 Sep 1; 39 (25):2803-2815 Epub 2021 June 02
    View PubMed
  18. Ou FS, Tang J, An MW, Mandrekar SJ. Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials. Contemp Clin Trials Commun. 2021 Sep; 23:100827 Epub 2021 Aug 09
    View PubMed
  19. Francini E, Ou FS, Rhoades J, Wolfe EG, O'Connor EP, Ha G, Gydush G, Kelleher KM, Bhatt RS, Balk SP, Sweeney CJ, Adalsteinsson VA, Taplin ME, Choudhury AD. Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021 Aug 12; 13 (16)
    View PubMed
  20. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist. 2021 Jul; 26 (7):610-618 Epub 2021 Mar 06
    View PubMed
  21. Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Ginos B, Heying E, Wu TT, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP, Alberts SR. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). Eur J Cancer. 2021 Jun; 150:214-223 Epub 2021 Apr 29
    View PubMed
  22. Lee S, Zhang S, Ma C, Ou FS, Wolfe EG, Ogino S, Niedzwiecki D, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Gross CP, Irwin ML, Meyerhardt JA, Fuchs CS. Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance). JNCI Cancer Spectr. 2021 Jun; 5 (3) Epub 2021 Apr 12
    View PubMed
  23. Ou FS, Michiels S, Shyr Y, Adjei AA, Oberg AL. Biomarker Discovery and Validation: Statistical Considerations. J Thorac Oncol. 2021 Apr; 16 (4):537-545 Epub 2021 Feb 02
    View PubMed
  24. Casulo C, Dixon JG, Ou FS, Hoster E, Peterson BA, Hochster HS, Brice P, Ladetto M, Hiddemann W, Marcus R, Kimby E, Herold M, Nielsen T, Morschhauser F, Rummel M, Hagenbeek A, Vitolo U, Salles GA, Shi Q, Flowers CR. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Adv. 2021 Mar 23; 5 (6):1737-1745
    View PubMed
  25. Iveson TJ, Sobrero AF, Yoshino T, Souglakos I, Ou FS, Meyers JP, Shi Q, Grothey A, Saunders MP, Labianca R, Yamanaka T, Boukovinas I, Hollander NH, Galli F, Yamazaki K, Georgoulias V, Kerr R, Oki E, Lonardi S, Harkin A, Rosati G, Paul J. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. J Clin Oncol. 2021 Feb 20; 39 (6):631-641 Epub 2021 Jan 13
    View PubMed
  26. Francini E, Ou FS, Lazzi S, Petrioli R, Multari AG, Pesola G, Messuti L, Colombo E, Livellara V, Bazzurri S, Cherri S, Miano ST, Wolfe EG, Alberts SR, Hubbard JM, Yoon HH, Francini G. The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. Transl Oncol. 2021 Feb; 14 (2):100973 Epub 2020 Dec 15
    View PubMed
  27. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Pollak MN, Nixon AB, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Benson AB 3rd, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr. 2021 Feb; 5 (1) Epub 2020 Aug 27
    View PubMed
  28. Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell SD, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, Kubo M, Lenz HJ, Parker JS, Ratain MJ, Owzar K. Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 Jan 1; 27 (1):267-275 Epub 2020 Sept 21
    View PubMed
  29. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28
    View PubMed
  30. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 Dec; 17 (12):757-770 Epub 2020 July 06
    View PubMed
  31. Ou FS, Le-Rademacher JG, Ballman KV, Adjei AA, Mandrekar SJ. Guidelines for Statistical Reporting in Medical Journals. J Thorac Oncol. 2020 Nov; 15 (11):1722-1726 Epub 2020 Aug 25
    View PubMed
  32. Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, O'Neil BH, Mullen BC, Lenz HJ, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg RM, O'Reilly EM, Meyerhardt JA, Ng K. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020 Nov 1; 6 (11):1713-1721
    View PubMed
  33. Van Blarigan EL, Zhang S, Ou FS, Venlo A, Ng K, Atreya C, Van Loon K, Niedzwiecki D, Giovannucci E, Wolfe EG, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. JAMA Netw Open. 2020 Oct 1; 3 (10):e2023500 Epub 2020 Oct 01
    View PubMed
  34. Cheng E, Zhang S, Ou FS, Mullen B, Ng K, Saltz LB, Niedzwiecki D, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Giovannucci EL, Van Blarigan EL, Meyerhardt JA, Fuchs CS. The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance). Cancer Epidemiol Biomarkers Prev. 2020 Aug; 29 (8):1692-1695 Epub 2020 June 04
    View PubMed
  35. Chakrabarti S, Zemla TJ, Ahn DH, Ou FS, Fruth B, Borad MJ, Hartgers ML, Wessling J, Walkes RL, Alberts SR, McWilliams RR, Liu MC, Durgin LM, Bekaii-Saab TS, Mahipal A. Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2020 May; 25 (5):380-e763 Epub 2019 Dec 11
    View PubMed
  36. Guercio BJ, Zhang S, Venook AP, Ou F-S, Niedzwiecki D, Lenz H-J, Innocenti F, Mullen BC, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Brown JC, O'Reilly EM, Mayer RJ, Blanke CD, Fuchs CS, Meyerhardt JA. Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405 JNCI Cancer Spectrum. 2020; 4(3).
  37. An MW, Tang J, Grothey A, Sargent DJ, Ou FS, Mandrekar SJ. Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemp Clin Trials Commun. 2020 Mar; 17:100492 Epub 2019 Nov 22
    View PubMed
  38. Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectr. 2020 Feb; 4 (1):pkz078 Epub 2019 Oct 17
    View PubMed
  39. Yuan C, Sato K, Hollis BW, Zhang S, Niedzwiecki D, Ou FS, Chang IW, O'Neil BH, Innocenti F, Lenz HJ, Blanke CD, Goldberg RM, Venook AP, Mayer RJ, Fuchs CS, Meyerhardt JA, Ng K. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2019 Dec 15; 25 (24):7497-7505 Epub 2019 Sept 23
    View PubMed
  40. Wei AC, Ou FS, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, Goff LW, Pisters P, Posner MC. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26 (13):4489-4497 Epub 2019 Aug 15
    View PubMed
  41. Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 Oct 10; 37 (29):2620-2631 Epub 2019 Aug 13
    View PubMed
  42. Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. Reply to S. Sorscher. J Clin Oncol 2019 Sep 1; 37 (25):2291-2293 Epub 2019 July 03
    View PubMed
  43. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Aug; 20 (8):1070-1082 Epub 2019 June 28
    View PubMed
  44. Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2019 Aug 1; 37 (22):1876-1885 Epub 2019 May 01
    View PubMed
  45. Song M, Ou FS, Zemla TJ, Hull MA, Shi Q, Limburg PJ, Alberts SR, Sinicrope FA, Giovannucci EL, Van Blarigan EL, Meyerhardt JA, Chan AT. Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). Int J Cancer. 2019 Jul 15; 145 (2):380-389 Epub 2019 Jan 28
    View PubMed
  46. Ou FS, Heller M, Shi Q. Milestone prediction for time-to-event endpoint monitoring in clinical trials. Pharm Stat. 2019 Jul; 18 (4):433-446 Epub 2019 Feb 26
    View PubMed
  47. Yuan C, Renfro L, Ambadwar PB, Ou FS, McLeod HL, Innocenti F, Meyerhardt JA, Wolpin BM, Goldberg RM, Grothey A, Fuchs CS, Ng K. Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer. Cancer Causes Control. 2019 Jul; 30 (7):757-765 Epub 2019 May 18
    View PubMed
  48. Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019 May 10; 37 (14):1217-1227 Epub 2019 Mar 13
    View PubMed
  49. Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer. 2019 Apr; 111:82-93 Epub 2019 Mar 01
    View PubMed
  50. Ou FS, An MW, Ruppert AS, Mandrekar SJ. Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies. JCO Precis Oncol. 2019; 3 Epub 2019 Oct 24
    View PubMed
  51. Shenoy N, Mudireddy M, Vallapureddy R, Leung N, Pagliaro L, Witzig T, Ou FS, Ordog T, Cheville J, Patnaik M, Thompson RH, Tefferi A, Begna K. Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning? Clin Genitourin Cancer. 2018 Dec; 16 (6):e1117-e1122 Epub 2018 June 28
    View PubMed
  52. Van Blarigan EL, Ou FS, Niedzwiecki D, Zhang S, Fuchs CS, Saltz L, Mayer RJ, Venook A, Ogino S, Song M, Benson A, Hantel A, Atkins JN, Giovannucci EL, Meyerhardt JA. Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev. 2018 Oct; 27 (10):1227-1230 Epub 2018 July 23
    View PubMed
  53. Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). J Clin Oncol. 2018 Sep 1; 36 (25):2593-2602 Epub 2018 July 05
    View PubMed
  54. Bekaii-Saab T, Ou F, Anderson D, Ahn D, Boland P, Ciombor K, Jacobs N, Desnoyers R, Cleary J, Meyers J, Chiorean E, Pedersen K, Barzi A, Sloan J, McCune J, Lacouture M, Lenz H, Grothey A. Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study. Ann Oncol. 2018 Jun; 29 Suppl 5:v105 Epub 2020 Jan 07
    View PubMed
  55. Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Borger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grutzmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Leonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Musina AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26; 391 (10135):2128-2139 Epub 2018 May 10
    View PubMed
  56. Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol. 2018 Feb 1; 29 (2):352-360
    View PubMed
  57. Stevens J, Truesdale KP, Cai J, Ou FS, Reynolds KR, Heymsfield SB. Nationally representative equations that include resistance and reactance for the prediction of percent body fat in Americans. Int J Obes (Lond). 2017 Nov; 41 (11):1669-1675 Epub 2017 July 24
    View PubMed
  58. Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E, Alliance for Clinical Trials on Oncology. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27; 17 (1):505 Epub 2017 July 27
    View PubMed
  59. Ou FS, Zeng D, Cai J. Quantile regression models for current status data J Stat Plan Inference. 2016 Nov; 178:112-27. Epub 2004 May 24.
    View PubMed
  60. Stevens J, Ou F-S, Truesdale KP, Zeng , D, Vaughn , AE, Pratt , C, Ward , DS. A suggested approach for imputation of missing dietary data for young children in daycare Food & Nutrition Research.08/26/2016;59:(10.3402/fnr.v59.28626):
    View PubMed
  61. Stevens J, Ou F, Cai J, Heymsfield SB, Truesdale KP. Prediction of percent body fat measurements in americans 8 years and older. Int J Obes (Lond).2016 Apr ;40:(4):587-94.
    View PubMed
  62. Mossavar-Rahmani Y, Shaw PA, Wong WW, Sotres-Alvarez D, Gellman MD, Van Horn L, Stoutenberg M, Daviglus ML, Wylie-Rosett J, Siega-Riz AM, Ou FS, Prentice RL. Applying Recovery Biomarkers to Calibrate Self-Report Measures of Energy and Protein in the Hispanic Community Health Study/Study of Latinos. Am J Epidemiol. 2015 Jun 15; 181(12):996-1007. Epub 2015 May 20.
    View PubMed
  63. Roshdy DG, Tran A, LeCroy N, Zeng D, Ou FS, Daniels LM, Weber DJ, Alby K, Miller MB. Impact of a rapid microarray-based assay for identification of positive blood cultures for treatment optimization for patients with streptococcal and enterococcal bacteremia. J Clin Microbiol. 2015 Apr; 53(4):1411-4. Epub 2015 Feb 11.
    View PubMed
  64. Martin SS, Ou FS, Newby LK, Sutton V, Adams P, Felker GM, Wang TY. Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials. J Am Coll Cardiol. 2013 Feb 19; 61(7):762-9.
    View PubMed
  65. Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, Wang TY, American College of Cardiology National Cardiovascular Data Registry. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013 Jan 15; 111(2):178-84. Epub 2012 Oct 27
    View PubMed
  66. Resnic FS, Wang TY, Arora N, Vidi V, Dai D, Ou FS, Matheny ME. Quantifying the learning curve in the use of a novel vascular closure device: an analysis of the NCDR (National Cardiovascular Data Registry) CathPCI registry. JACC Cardiovasc Interv. 2012 Jan; 5(1):82-9.
    View PubMed
  67. Glickman SW, Lytle BL, Ou FS, Mears G, O'Brien S, Cairns CB, Garvey JL, Bohle DJ, Peterson ED, Jollis JG, Granger CB. Care processes associated with quicker door-in-door-out times for patients with ST-elevation-myocardial infarction requiring transfer: results from a statewide regionalization program. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):382-8. Epub 2011 Jun 28.
    View PubMed
  68. Abtahian F, Olenchock B, Ou FS, Kontos MC, Saucedo JF, Scirica BM, Desai N, Peterson E, Roe M, Cannon CP, Wiviott SD. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011 May 15; 107(10):1441-6. Epub 2011 Mar 21.
    View PubMed
  69. Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, Harding T, Peterson ED, Alexander KP. Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome. Am Heart J. 2011 May; 161(5):855-63.
    View PubMed
  70. Williams JB, Delong ER, Peterson ED, Dokholyan RS, Ou FS, Ferguson TB Jr, Society of Thoracic Surgeons and the National Cardiac Database. Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice. Circulation. 2011 Jan 4; 123(1):39-45. Epub 2010 Dec 20
    View PubMed
  71. Burjonroppa SC, Varosy PD, Rao SV, Ou FS, Roe M, Peterson E, Singh M, Shunk KA. Survival of patients undergoing rescue percutaneous coronary intervention: development and validation of a predictive tool. JACC Cardiovasc Interv. 2011 Jan; 4 (1):42-50
    View PubMed
  72. Wang TY, Peterson ED, Ou FS, Nallamothu BK, Rumsfeld JS, Roe MT. Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: a report from the national cardiovascular data registry. Am Heart J. 2011 Jan; 161(1):76-83.e1.
    View PubMed
  73. Melloni C, Shah BR, Ou FS, Roe MT, Smith SC Jr, Pollack CV Jr, Ohman M, Gibler WB, Peterson ED, Alexander KP. Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry. Am Heart J. 2010 Dec; 160(6):1121-9, 1129.e1.
    View PubMed
  74. Kim MS, Wang TY, Ou FS, Klein AJ, Hudson PA, Messenger JC, Masoudi FA, Rumsfeld JS, Ho PM. Association of prior coronary artery bypass graft surgery with quality of care of patients with non-ST-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. Am Heart J. 2010 Nov; 160(5):951-7.
    View PubMed
  75. Kontos MC, de Lemos JA, Ou FS, Wiviott SD, Foody JM, Newby LK, Chen A, Roe MT. Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. Am Heart J. 2010 Nov; 160(5):819-25.
    View PubMed
  76. Glickman SW, Granger CB, Ou FS, O'Brien S, Lytle BL, Cairns CB, Mears G, Hoekstra JW, Garvey JL, Peterson ED, Jollis JG. Impact of a statewide ST-segment-elevation myocardial infarction regionalization program on treatment times for women, minorities, and the elderly. Circ Cardiovasc Qual Outcomes. 2010 Sep; 3(5):514-21. Epub 2010 Aug 31.
    View PubMed
  77. Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, Harding T, Alexander KP, Peterson ED. Changes in beliefs about medications during long-term care for ischemic heart disease. Am Heart J. 2010 Apr; 159(4):561-9.
    View PubMed
  78. Bangalore S, Messerli FH, Ou FS, Tamis-Holland J, Palazzo A, Roe MT, Hong MK, Peterson ED, CRUSADE Investigators. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J. 2010 Mar; 31(5):552-60. Epub 2009 Sep 30
    View PubMed
  79. Amsterdam EA, Peterson ED, Ou FS, Newby LK, Pollack CV Jr, Gibler WB, Ohman EM, Roe MT. Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. Am Heart J. 2009 Nov; 158(5):748-754.e1.
    View PubMed
  80. Ali RC, Melloni C, Ou FS, Schmader K, Ohman EM, Roe MT, Peterson ED, Alexander KP. Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time. J Am Geriatr Soc. 2009 Nov; 57(11):1990-6. Epub 2009 Sep 15.
    View PubMed
  81. Takakuwa KM, Ou FS, Peterson ED, Pollack CV Jr, Peacock WF, Hoekstra JW, Ohman EM, Gibler WB, Blomkalns AL, Roe MT. The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. Clin Cardiol. 2009 Sep; 32(9):498-505.
    View PubMed
  82. Melloni C, Alexander KP, Ou FS, LaPointe NM, Roe MT, Newby LK, Baloch K, Ho PM, Rumsfeld JS, Peterson ED. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol. 2009 Jul 15; 104(2):175-81. Epub 2009 Jun 03.
    View PubMed
  83. Chandra A, Glickman SW, Ou FS, Peacock WF, McCord JK, Cairns CB, Peterson ED, Ohman EM, Gibler WB, Roe MT. An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. Ann Emerg Med. 2009 Jul; 54(1):17-25. Epub 2009 Mar 12.
    View PubMed
  84. Kutcher MA, Klein LW, Ou FS, Wharton TP Jr, Dehmer GJ, Singh M, Anderson HV, Rumsfeld JS, Weintraub WS, Shaw RE, Sacrinty MT, Woodward A, Peterson ED, Brindis RG, National Cardiovascular Data Registry. Percutaneous coronary interventions in facilities without cardiac surgery on site: a report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol. 2009 Jun 30; 54(1):16-24. Epub 1900 Jan 01.
  85. Spinler SA, Ou FS, Roe MT, Gibler WB, Ohman EM, Pollack CV, Alexander KP, Peterson ED. Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy. 2009 Jun; 29(6):631-8.
    View PubMed
  86. Mehta SK, Frutkin AD, Lindsey JB, House JA, Spertus JA, Rao SV, Ou FS, Roe MT, Peterson ED, Marso SP, National Cardiovascular Data Registry. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2009 Jun; 2(3):222-9. Epub 2009 May 8
    View PubMed
  87. Wang TY, Ou FS, Roe MT, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009 May 12; 119(18):2454-62. Epub 2009 Apr 27.
    View PubMed
  88. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, Roe MT, CRUSADE Investigators. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202. Epub 2009 Apr 1
    View PubMed
  89. Cardarelli F, Bellasi A, Ou FS, Shaw LJ, Veledar E, Roe MT, Morris DC, Peterson ED, Klein LW, Raggi P. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am J Cardiol. 2009 Mar 15; 103(6):766-71. Epub 2009 Jan 24.
    View PubMed
  90. Patel UD, Ou FS, Ohman EM, Gibler WB, Pollack CV Jr, Peterson ED, Roe MT. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. Am J Kidney Dis. 2009 Mar; 53(3):426-37. Epub 2008 Dec 19.
    View PubMed
  91. Bangalore S, Messerli FH, Ou FS, Tamis-Holland J, Palazzo A, Roe MT, Hong MK, Peterson ED, CRUSADE Investigators. Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: results from 139,194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative. Am Heart J. 2009 Mar; 157(3):525-31. Epub 2009 Jan 8
    View PubMed
  92. Singh M, Peterson ED, Roe MT, Ou FS, Spertus JA, Rumsfeld JS, Anderson HV, Klein LW, Ho KK, Holmes DR. Trends in the association between age and in-hospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience. Circ Cardiovasc Interv. 2009 Feb; 2 (1):20-6 Epub 2009 Feb 10
    View PubMed
  93. Mehta RH, Ou FS, Peterson ED, Shaw RE, Hillegass WB Jr, Rumsfeld JS, Roe MT, American College of Cardiology-National Cardiovascular Database Registry Investigators. Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention. JACC Cardiovasc Interv. 2009 Jan; 2(1):56-64.
    View PubMed
  94. Alexander D, Mann N, Ou FS, Peterson ED, Ohman EM, Gibler WB, Roe MT. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). Am J Cardiol. 2008 Nov 15; 102(10):1335-40. Epub 2008 Sep 06.
    View PubMed
  95. Roe MT, Ou FS, Alexander KP, Newby LK, Foody JM, Gibler WB, Boden WE, Ohman EM, Smith SC Jr, Peterson ED. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2008 Oct; 29(20):2480-8. Epub 2008 Aug 20.
    View PubMed
  96. Alexander D, Ou FS, Roe MT, Pollack CV Jr, Ohman EM, Cannon CP, Gibler WB, Fintel DJ, Peterson ED, Brown DL, American College of Cardiology/American Heart Association. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Am Heart J. 2008 Sep; 156(3):606-12. Epub 2008 Jul 22
    View PubMed
  97. Rao SV, Ou FS, Wang TY, Roe MT, Brindis R, Rumsfeld JS, Peterson ED. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2008 Aug; 1(4):379-86.
    View PubMed
  98. Karve AM, Ou FS, Lytle BL, Peterson ED. Potential unintended financial consequences of pay-for-performance on the quality of care for minority patients. Am Heart J. 2008 Mar; 155(3):571-6.
    View PubMed
  99. Ting HH, Roe MT, Gersh BJ, Spertus JA, Rumsfeld JS, Ou FS, Kao J, Long KH, Holmes DR Jr, Peterson ED, National Cardiovascular Data Registry (NCDR). Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol. 2008 Feb 1; 101 (3):286-92
    View PubMed
  100. Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB, Smith SC Jr, Peterson ED, Becker RC. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J. 2008 Feb; 155(2):361-8. Epub 2007 Oct 25.
    View PubMed
  101. Glickman SW, Ou FS, DeLong ER, Roe MT, Lytle BL, Mulgund J, Rumsfeld JS, Gibler WB, Ohman EM, Schulman KA, Peterson ED. Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA. 2007 Jun 6; 297(21):2373-80.
    View PubMed